SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy

BACKGROUND: The impact of pretreatment factors on immune checkpoint inhibition in platinum-refractory advanced urothelial cancer (aUC) deserves further evaluation. The aim was to study the association of Bellmunt risk factors, time from last chemotherapy (TFLC), previous therapy and PD-L1 expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamias, A., Merseburger, A.S., Loriot, Y., James, N., Choy, E., Castellano, D., Lopez-Rios, F., Calabrò, F., Kramer, M., de Velasco, G., Zakopoulou, R., Tzannis, K., Sternberg, C.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134736/
https://www.ncbi.nlm.nih.gov/pubmed/33984672
http://dx.doi.org/10.1016/j.esmoop.2021.100152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134736/
https://www.ncbi.nlm.nih.gov/pubmed/33984672
http://dx.doi.org/10.1016/j.esmoop.2021.100152

Ejemplares similares